Education and Training
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Surfactant
- device: Continuous Positive Airway Pressure (CPAP)
- drug: Supplemental oxygen with target saturation of 85 to 89%
- drug: Supplemental oxygen with target saturation of 91 to 95%
Eligibility
Inclusion Criteria:
- Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to
27 6/7ths) by best obstetrical estimate
- Infants who will receive full resuscitation as necessary, i.e., no parental request or
physician decision to forego resuscitation
- Infants whose parents/legal guardians have provided consent for enrollment, or
- Infants without known major congenital malformations
Exclusion Criteria:
- Any infant transported to the center after delivery
- Infants whose parents/legal guardians refuse consent
- Infants born during a time when the research apparatus/study personnel are not
available
- Infants < 24 weeks 0 days or > 28 weeks 0 days, completed weeks of gestation
Ages Eligible for Study
24 Weeks - 27 Weeks
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Krisa Van Meurs, MD
Not Recruiting